Finadyne for Horses | 
Finadyne is a powerful anti-inflammatory and pain relieving drug for use in horses. It is usually used for musculo-skeletal problems in horses, including joint injuries. Finadyne also has anti-endotoxic and anti-fever properties, so can be used as an aid in other medical conditions and infections. Finadyne is normally given once daily for up to five days.
To read about the individual products, click on the product name below.
| | | | |
| Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: MSD Animal Health
Address: Walton Manor
Walton
Milton Keynes
MK7 7AJ
Telephone: 01908 685685 (Customer Support Centre)
Fax: 01908 685555
Email: vet-support.uk@merck.com
Website: www.msd-animal-health.co.uk
Presentation
White to cream coloured granules containing 250 mg flunixin, as flunixin meglumine BP (Vet) per 10 gram packet.
Uses
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities. Finadyne Granules are indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders in the horse.
Dosage and administration
Finadyne Granules are for oral administration only.
The recommended dosage is the contents of one packet (10 g) Finadyne Granules per 227 kg (500 lb) bodyweight (equivalent to 1.1 mg flunixin per kg) once daily for up to five consecutive days according to clinical response.
Finadyne Granules are easily administered by sprinkling on a small amount of food.
Contra-indications, warnings, etc
Do not exceed the stated dose or the duration of treatment.
Do not administer to pregnant mares. Studies to demonstrate safety in pregnant mares have not been conducted.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
It is preferable that NSAID’s which inhibit prostaglandin synethesis are not administered to animals undergoing general anaesthesia until fully recovered.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.
Operator warnings
Direct contact with the skin should be kept to a minimum.
Avoid contact with eyes. If contact occurs rinse immediately with clear running water.
Wash hands after use.
Withdrawal period
Animals must not be slaughtered for human consumption during treatment.
Horses may be slaughtered for human consumption only after 7 days from the last treatment.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Sprinkle on feed immediately before administration. Discard any remaining feed.
Dispose of any unused product in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Packaging Quantities
Packets containing 10 g Finadyne Granules in boxes of 10 packets.
Further information
Flunixin meglumine is also presented as Finadyne Solution and Finadyne Paste which may be used as an alternative to Finadyne Granules. A suggested dosage regime is an initial injection of Finadyne Solution followed by Finadyne Granules or Finadyne Paste on subsequent days.
Studies in horses have shown onset of activity occurs two hours after oral administration. Peak response occurs between 12 and 16 hours and the duration of activity is 24 to 36 hours.
Veterinary Surgeons administering NSAIDs to racehorses should refer to Section 4.4 of the RCVS Guide to Professional Conduct. Section 4.4.7 states, ''If a veterinarian recommends the discontinuance of any substance . . . not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional cases''.
Marketing authorisation number
Vm 00201/4008.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: MSD Animal Health
Address: Walton Manor
Walton
Milton Keynes
MK7 7AJ
Telephone: 01908 685685 (Customer Support Centre)
Fax: 01908 685555
Email: vet-support.uk@merck.com
Website: www.msd-animal-health.co.uk
Presentation
Syringe with white to off-white oral paste containing 5% w/w Flunixin (as Flunixin meglumine).
Uses
For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.
Dosage and administration
For oral administration only.
1.1 mg flunixin per kg bodyweight once daily for up to 5 days according to clinical response.
Each syringe is sufficient for one day’s treatment for a 445 kg (1000 lb.) horse. The syringe is calibrated in 100 kg increments to facilitate dosing of horses of different weights.
Contra-indications, warnings, etc
Flunixin meglumine is a non-steroidal anti-inflammatory drug.
Do not administer to pregnant mares. Safety studies in pregnant mares have not been conducted.
Do not exceed the stated dose or duration of treatment.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Do not administer other NSAID’s concurrently or within 24 hours of each other.
Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.
Avoid use in dehydrated, hypovolaemic or hypersensitive animals as there is a potential risk of increased renal toxicity.
Non-steroidal anti-inflammatory drugs are not permitted substances under the rules of racing and under rules covering other competitive events. The Royal College of Veterinary Surgeons has given guidance to the Veterinary profession regarding the use of anti-inflammatory drugs in competing horses. It states that if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing he should feel sure he has catered for all but the most exceptional case.
Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.
NSAID’s can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.
Overdosage studies in the target species have shown the product to be well-tolerated. Overdosage is associated with gastrointestinal toxicity.
Interactions
Concurrent administration of potentially nephrotoxic drugs should be avoided.
Some NSAIDs may be highly bound to plasma proteins and may compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations which can lead to toxic effects.
Operator warnings
Avoid contact with eyes and direct contact with skin. Gloves should be worn during application.
In the case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.
The product may cause reactions in sensitive individuals. If you have known hypersensitivity to non-steroidal anti-inflammatory products, do not handle the product. Reactions may be serious.
Wash hands and exposed skin after use.
Withdrawal period(s)
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Do not freeze. Replace cap after use.
Disposal advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
Carton containing 6 syringes.
10 g or 30 g natural low density white polyethylene syringe barrel and polypropylene dial-a-dose plunger with low density polyethylene cap and plunger seal.
Not all pack sizes may be marketed.
Further information
Nil.
Marketing authorisation number
Vm 00201/4012.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: MSD Animal Health
Address: Walton Manor
Walton
Milton Keynes
MK7 7AJ
Telephone: 01908 685685 (Customer Support Centre)
Fax: 01908 685555
Email: vet-support.uk@merck.com
Website: www.msd-animal-health.co.uk
Presentation
A clear, light yellow, sterile solution for injection containing 50 mg flunixin, as flunixin meglumine BP (Vet), and 5 mg phenol Ph Eur as a preservative, per ml.
Uses
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
In the horse, Finadyne Solution is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic.
In cattle, Finadyne Solution is indicated for the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever).
In cattle, Finadyne may be used as adjunctive therapy in the treatment of acute mastitis.
In pigs, Finadyne Solution is indicated for use as an adjunctive therapy in the treatment of swine respiratory diseases
Dosage and administration
For use in equine musculo-skeletal disorders, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously once daily for up to five days according to clinical response.
For use in equine colic, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) by intravenous injection. Treatment may be repeated once or twice if colic recurs. The cause of colic should be determined and treated with concomitant therapy.
For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which circulation of blood to the gastrointestinal tract is impaired, the recommended dosage is 1 ml per 200 kg bodyweight (0.25 mg/kg) administered every 6–8 hours.
For use in bovine acute inflammatory conditions, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of the acute inflammatory condition should be determined and treated with concomitant therapy.
For use in pigs, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in conjunction with appropriate antimicrobial therapy. The injection volume should be limited to a maximum of 5 ml per injection site.
An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes.
In order to prevent excessive broaching of the rubber stopper, it is not recommended that the stopper is broached more than 25 times.
Contra-indications, warnings, etc
Do not exceed the stated dose or the duration of treatment.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Do not administer to pregnant mares.
Do not administer to pregnant sows, gilts at mating and in breeding boars.
Special precautions for use in animals
Avoid intra-arterial injection.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
The cause of colic should be determined and treated with concurrent therapy.
The product should not be used in piglets weighing less than 6 kg.
Special Precautions to be taken by the Person Administering the Product to the Animal
Avoid contact with skin or eyes.
In case of skin contact, wash exposed area with water.
In case of eye contact, wash eyes thoroughly with clean water and seek medical advice.
Take care against accidental self injection.
Wash hands after use.
Special warnings, interactions etc.
Non-steroidal, anti-inflammatory drugs are not permitted under the rules of Racing and under rules covering other competitive events.
The Royal College of Veterinary Surgeons has given advice to the Veterinary Profession regarding the use of anti-inflammatory drugs in competing horses. It states that "if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing, he should feel sure that he has catered for all but the most exceptional case".
Do not exceed the recommended dose or duration of treatment.
Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). Untoward effects include gastro-intestinal irritation, ulceration and, in dehydrated or hypovolaemic animals, potential for renal damage.
In pigs, transient irritation may occur at the injection site, this resolves spontaneously within 14 days.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
The product may be used in pregnant and lactating cattle.
Do not use in pregnant mares or pregnant sows. Safety studies in pregnant mares and pregnant sows have not been conducted.
Overdosage studies in the target species have shown the product to be well-tolerated. Flunixin meglumine is a non-steroidal anti-inflammatory drug. Overdosage is associated with gastrointestinal toxicity. Concurrent use of nephrotoxic drugs should be avoided.
Withdrawal periods
Animals must not be slaughtered for human consumption during treatment.
Cattle: 5 days from the last treatment.
Horses: 7 days from the last treatment.
Pigs: 22 days from the last treatment.
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 24 hours from the last treatment.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Do not freeze.
Following withdrawal of the first dose, use within 28 days. Discard unused material. Unused product and any waste material should be disposed of in accordance with guidance from an appropriate waste regulation authority.
Legal category
POM-V
Packaging Quantities
50 ml and 100 ml glass vials.
Further information
Flunixin meglumine is also presented as Finadyne Granules and Finadyne Paste which may be used as an alternative to Finadyne Solution in musculo-skeletal indications in the horse. A suggested dosage regime is an initial injection of Finadyne Solution followed by Finadyne Granules or Finadyne Paste on subsequent days.
Studies in horses have shown onset of activity occurs two hours after parenteral administration when used in musculo-skeletal disorders. Peak response occurs between 12 and 16 hours and the duration of activity is 24 to 36 hours. When used in equine colic, studies have shown alleviation of pain within 15 minutes in many cases. During clinical studies, approximately 10% of the horses required one or two additional treatments.
Veterinary Surgeons administering NSAIDs to racehorses should refer to Section 4.4 of the RCVS Guide to Professional Conduct. Section 4.4.7 states, ''If a veterinarian recommends the discontinuance of any substance . . . not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional cases''.
Marketing authorisation number
Vm 00201/4009.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: MSD Animal Health
Address: Walton Manor
Walton
Milton Keynes
MK7 7AJ
Telephone: 01908 685685 (Customer Support Centre)
Fax: 01908 685555
Email: vet-support.uk@merck.com
Website: www.msd-animal-health.co.uk
Presentation
A clear, light yellow, sterile solution for injection containing 50 mg flunixin, as flunixin meglumine BP (Vet), and 5 mg phenol Ph Eur as a preservative, per ml.
Uses
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
In the horse, Finadyne Solution is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic.
In cattle, Finadyne Solution is indicated for the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever).
In cattle, Finadyne may be used as adjunctive therapy in the treatment of acute mastitis.
In pigs, Finadyne Solution is indicated for use as an adjunctive therapy in the treatment of swine respiratory diseases
Dosage and administration
For use in equine musculo-skeletal disorders, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously once daily for up to five days according to clinical response.
For use in equine colic, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) by intravenous injection. Treatment may be repeated once or twice if colic recurs. The cause of colic should be determined and treated with concomitant therapy.
For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which circulation of blood to the gastrointestinal tract is impaired, the recommended dosage is 1 ml per 200 kg bodyweight (0.25 mg/kg) administered every 6–8 hours.
For use in bovine acute inflammatory conditions, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of the acute inflammatory condition should be determined and treated with concomitant therapy.
For use in pigs, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in conjunction with appropriate antimicrobial therapy. The injection volume should be limited to a maximum of 5 ml per injection site.
An appropriately graduated syringe must be used to allow accurate administration of the required dose volume. This is particularly important when injecting small volumes.
In order to prevent excessive broaching of the rubber stopper, it is not recommended that the stopper is broached more than 25 times.
Contra-indications, warnings, etc
Do not exceed the stated dose or the duration of treatment.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Do not administer to pregnant mares.
Do not administer to pregnant sows, gilts at mating and in breeding boars.
Special precautions for use in animals
Avoid intra-arterial injection.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
The cause of colic should be determined and treated with concurrent therapy.
The product should not be used in piglets weighing less than 6 kg.
Special Precautions to be taken by the Person Administering the Product to the Animal
Avoid contact with skin or eyes.
In case of skin contact, wash exposed area with water.
In case of eye contact, wash eyes thoroughly with clean water and seek medical advice.
Take care against accidental self injection.
Wash hands after use.
Special warnings, interactions etc.
Non-steroidal, anti-inflammatory drugs are not permitted under the rules of Racing and under rules covering other competitive events.
The Royal College of Veterinary Surgeons has given advice to the Veterinary Profession regarding the use of anti-inflammatory drugs in competing horses. It states that "if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing, he should feel sure that he has catered for all but the most exceptional case".
Do not exceed the recommended dose or duration of treatment.
Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). Untoward effects include gastro-intestinal irritation, ulceration and, in dehydrated or hypovolaemic animals, potential for renal damage.
In pigs, transient irritation may occur at the injection site, this resolves spontaneously within 14 days.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
The product may be used in pregnant and lactating cattle.
Do not use in pregnant mares or pregnant sows. Safety studies in pregnant mares and pregnant sows have not been conducted.
Overdosage studies in the target species have shown the product to be well-tolerated. Flunixin meglumine is a non-steroidal anti-inflammatory drug. Overdosage is associated with gastrointestinal toxicity. Concurrent use of nephrotoxic drugs should be avoided.
Withdrawal periods
Animals must not be slaughtered for human consumption during treatment.
Cattle: 5 days from the last treatment.
Horses: 7 days from the last treatment.
Pigs: 22 days from the last treatment.
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 24 hours from the last treatment.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Do not freeze.
Following withdrawal of the first dose, use within 28 days. Discard unused material. Unused product and any waste material should be disposed of in accordance with guidance from an appropriate waste regulation authority.
Legal category
POM-V
Packaging Quantities
50 ml and 100 ml glass vials.
Further information
Flunixin meglumine is also presented as Finadyne Granules and Finadyne Paste which may be used as an alternative to Finadyne Solution in musculo-skeletal indications in the horse. A suggested dosage regime is an initial injection of Finadyne Solution followed by Finadyne Granules or Finadyne Paste on subsequent days.
Studies in horses have shown onset of activity occurs two hours after parenteral administration when used in musculo-skeletal disorders. Peak response occurs between 12 and 16 hours and the duration of activity is 24 to 36 hours. When used in equine colic, studies have shown alleviation of pain within 15 minutes in many cases. During clinical studies, approximately 10% of the horses required one or two additional treatments.
Veterinary Surgeons administering NSAIDs to racehorses should refer to Section 4.4 of the RCVS Guide to Professional Conduct. Section 4.4.7 states, ''If a veterinarian recommends the discontinuance of any substance . . . not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional cases''.
Marketing authorisation number
Vm 00201/4009.
| 
